S784 Sustained Symptom Control With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis in the LUCENT-2 Maintenance Trial. (October 2022) - Dignass, Axel; Danese, Silvio; Matsuoka, Katsuyoshi; Ferrante, Marc; Redondo, Isabel; Gibble, Theresa Hunter; Moses, Richard; Li, Xingyuan; Morris, Nathan; Milch, Catherine; Abreu, Maria T.